A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Mild cognitive impairment
  • Focus Registrational; Therapeutic Use
  • Acronyms HOPE4MCI
  • Sponsors AgeneBio
  • Most Recent Events

    • 03 Apr 2018 Status changed from planning to not yet recruiting.
    • 19 Sep 2017 According to an AgeneBio media release, company has been awarded an additional grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and company expects to enroll the first patient during the first quarter of 2018
    • 15 Sep 2015 According to an AgeneBio media release, the National Institutes of Health (NIH) has granted a five year $7.5 million grant to AgeneBio for the study of AGB101 and its potential to prevent or delay the onset of Alzheimer's dementia. This trial is expected to be initiated in early 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top